1. Search Result
Search Result
Results for "

insulin secretagogue

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15209
    Repaglinide
    2 Publications Verification

    AG-EE 623ZW

    Potassium Channel Metabolic Disease Cancer
    Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .
    Repaglinide
  • HY-W040127
    Peonidin 3-O-glucoside chloride
    1 Publications Verification

    Insulin Receptor Metabolic Disease
    Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .
    Peonidin 3-O-glucoside chloride
  • HY-15589
    GW9508
    Maximum Cited Publications
    7 Publications Verification

    Free Fatty Acid Receptor Potassium Channel Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508
  • HY-10199A
    Ibutamoren
    5 Publications Verification

    MK-677 free base; MK-0677 free base

    GHSR Insulin Receptor Neurological Disease Metabolic Disease
    Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis .
    Ibutamoren
  • HY-15209S

    AG-EE 623ZW d5

    Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Repaglinide-d5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .
    Repaglinide-d5
  • HY-W017387
    Sodium α-ketoisocaproate
    1 Publications Verification

    Sodium 4-methyl-2-oxopentanoate; 2-Ketoisocaproic acid sodium salt

    Branched Chain Amino Acid Transaminase (BCAT) Potassium Channel Na+/Ca2+ Exchanger Metabolic Disease
    Sodium α-ketoisocaproate (Sodium 4-methyl-2-oxopentanoate) is an insulin secretagogue. Sodium α-ketoisocaproate undergoes transamination catalyzed by BCAT and BCATm to produce α-ketoglutarate and leucine; it also binds to the SUR1 site to inhibit KATP channel activity, but does not directly affect the Kir6.2 subunit. Sodium α-ketoisocaproate regulates Ca 2+ influx. Sodium α-ketoisocaproate exerts insulinotropic activity in pancreatic islets and intact mouse pancreata with sufficient BCATm expression. Sodium α-ketoisocaproate can be used in research related to type 2 diabetes .
    Sodium α-ketoisocaproate
  • HY-112819

    Insulin Receptor Metabolic Disease
    Insulin levels modulator (Example 49) is an orally active insulin secretagogue. Insulin levels modulator can be used for the research of type 2 diabetes and type 2 diabetes-related disorders .
    Insulin levels modulator
  • HY-15209R

    AG-EE 623ZW (Standard)

    Reference Standards Potassium Channel Metabolic Disease Cancer
    Repaglinide (Standard) is the analytical standard of Repaglinide. This product is intended for research and analytical applications. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .
    Repaglinide (Standard)
  • HY-15589R

    Free Fatty Acid Receptor Potassium Channel Reference Standards Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508 (Standard)
  • HY-111141

    Free Fatty Acid Receptor Metabolic Disease
    AM-3189 is an orally active and selective GPR40 agonist with EC50 values in buffer solution and in 100% human serum of 33 nM and 10 μM respectively. AM-3189 shows no significant activity on GPR41 and GPR43, and no agonistic activity on PPAR-α, -δ, and -γ. AM-3189 enhances glucose-stimulated insulin secretion by activating GPR40 on pancreatic β cells. AM-3189 has extremely low penetration into the central nervous system and significantly reduces blood glucose levels in two humanized GPR40 mouse models. AM-3189 can be used for the study of type 2 diabetes .
    AM-3189

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: